Mechanistically, our study demonstrates that β-PGG treatment significantly reduced PCID2 expression in HCC cells, accompanied by downregulation of Cyclin D1 and CDK6, two key regulators of the G1-to-S phase transition. The gene discussed is CCND1; the disease is hepatocellular carcinoma.